<u>REMARKS</u>

The above additions to the claims find basis in the original disclosure generally at page 12, lines 2 - 12, and at page 16, line 2 to page 18, line 10. Page 6, lines 5 - 20 refer to the use of the specific terms "analyte", "molecular fragmentation" "fragment ions". By its definition within the specification, immunologic complexes and fragments thereof are therefore included. Page 28, lines 3 - 23 refer to the use of samples which are a variety of blood and blood products and their measurement. Page 29, line 4 refers to known immunoassay techniques and provides an article by Takahashi which is incorporated by reference (page 33, line 3). This article describes the standard use of obtaining more than one sample and at different time periods. Page 31, lines 6 -8 refer to the use of polyclonal antibodies produced in an animal host. Page 14, lines 18 - 22 refer to the therapeutic avenues to be developed based on interactions observed such as within the complement system in order to regulate the progression of disease involving a form of a biopolymer. It is clear from these specific recitations and from the description of methods utilized to develop therapies based on the specific biopolymer disclosed that the

methods, types of kits and antibodies were fully contemplated by the inventor at the time of filing and were enabled by virtue of the disclosure as originally filed.

Respectfully submitted,

Ferris H. Lander

Registration # 43,377

Date: August 10, 2001

McHale & Slavin, P.A. 4440 PGA Blvd., Suite 402 Palm Beach Gardens, FL 33402 (561) 625-6575 (Voice) (561) 625-6572 (Fax)

G:\FILES\EPM\Amendments\2132_029_pre.am.wpd